Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Factors for Repair Integrity After Arthroscopic Rotator Cuff Repair: A Systematic Review and Meta-analysis.

Orthopaedic journal of sports medicine·2026
Same author

CellVizio<sup>®</sup> System for Mesothorax Lymphadenopathy Rapid on Site, 18G needle: Pros and Cons.

Journal of Cancer·2026
Same author

Could fructosamine be used in the glycemic monitoring of individuals with a history of gestational diabetes mellitus?

Diabetes & metabolic syndrome·2026
Same author

Early interventions for the prevention of preeclampsia in pregnant women at increased risk: a network meta-analysis.

The Cochrane database of systematic reviews·2026
Same author

Medical Screening of Adult Psychiatric Patients Presenting to the Emergency Department.

Annals of emergency medicine·2026
Same author

Viral Genomic Footprints in Breast Cancer: A Systematic Review and Meta-Analysis of Tissue-Based Detection of Epstein-Barr Virus and Bovine Leukemia Virus.

International journal of molecular sciences·2026

Related Experiment Video

Updated: May 6, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.7K

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic

Stamatios Petousis1, Ilker Kahramanoglu2, Christian Appenzeller-Herzog3

  • 1Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

JAMA Network Open
|November 5, 2025
PubMed
Summary

First-line poly(adenosine diphosphate-ribose) polymerase inhibitor (PARP inhibitor) maintenance therapy improves progression-free survival (PFS) in advanced ovarian cancer but does not significantly improve overall survival (OS). Treatment efficacy and side effects vary by patient subgroup and specific PARP inhibitor.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.1K

Related Experiment Videos

Last Updated: May 6, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.1K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • First-line maintenance therapy with poly(adenosine diphosphate-ribose) polymerase inhibitors (PARP inhibitors) improves progression-free survival (PFS) in advanced epithelial ovarian cancer (EOC), especially in BRCA-variant or homologous recombination-deficient tumors.
  • Overall survival (OS) benefits and safety profiles necessitate further investigation for optimized patient and agent selection.

Purpose of the Study:

  • To evaluate the efficacy and safety of first-line PARP inhibitor maintenance therapy versus chemotherapy alone in advanced-stage EOC.
  • To conduct subgroup analyses based on BRCA and homologous recombination deficiency (HRD) status, surgical timing, chemotherapy response, and residual disease.

Main Methods:

  • A systematic review and meta-analysis of 7 randomized clinical trials involving 4013 patients with advanced-stage EOC.
  • Data extraction and synthesis followed PRISMA guidelines, using random-effects models and assessed for risk of bias and certainty of evidence.

Main Results:

  • PARP inhibitor maintenance significantly improved PFS in the overall population and most molecular subgroups, with high certainty.
  • No statistically significant improvement in OS was observed across any molecular subgroup.
  • High-grade adverse events were more frequent with PARP inhibitors, and efficacy and toxicity varied across different PARP inhibitor regimens.

Conclusions:

  • First-line PARP inhibitor maintenance therapy demonstrates consistent PFS benefits in advanced EOC but lacks significant OS improvement across subgroups.
  • Variability in efficacy and toxicity highlights the need for individualized treatment decisions based on patient-specific factors and PARP inhibitor choice.